At a glance
Effects
- Endurance / exercise capacity: Mouse models treated with SLU-PP-332 showed 20–30% improvements in running distance and time vs. controls, alongside increased oxidative type IIa muscle fibres [2][4].
- Fat mass reduction: Preclinical studies in obese mouse models demonstrated significantly decreased fat mass accumulation and enhanced fatty acid oxidation [5][7].
- Improved insulin sensitivity: ERR agonism reduced obesity and improved insulin sensitivity in diet-induced obese and ob/ob mouse models [5][7].
- Increased energy expenditure: Whole-body metabolic studies in mice showed increased resting energy expenditure without changes in food intake [7].
- Mitochondrial biogenesis: Enhances mitochondrial function and cellular respiration in skeletal muscle, recapitulating key adaptations of endurance training [4][5].
- Potential cardiac protection: ERR agonism has shown cardioprotective effects in pressure-overload heart failure models in preclinical research, linked to maintained oxidative metabolism in cardiomyocytes [8].
Pan-ERR (ERRα/β/γ) agonist · Exercise mimetic · Research compound only
Not established in humans; rodent estimate ~8–10 h (preclinical only) [14]
Intraperitoneal injection in all published studies; human route unvalidated. Oral bioavailability reportedly poor or absent [13]
No FDA approval · No IND · No registered human clinical trials · Research use only [9]
98 nM (in vitro) [3]
About SLU-PP-332
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor (ERR) family — orphan nuclear receptors that govern mitochondrial biogenesis and oxidative metabolism — developed at Saint Louis University [1]. It is classified as a pharmacological exercise mimetic, studied in preclinical models for its ability to reproduce cellular adaptations of aerobic exercise without physical activity [2].
How it works
SLU-PP-332 binds and activates all three ERR isoforms (ERRα, ERRβ, ERRγ), with highest potency at ERRα (EC50 ≈ 98 nM) [1][3]. ERRα activation upregulates PGC-1α — the master regulator of mitochondrial biogenesis — driving increased fatty acid oxidation, enhanced oxidative phosphorylation, and induction of gene programs associated with aerobic exercise [4][5]. In skeletal muscle this promotes a shift toward oxidative (type IIa) muscle fibres, closely mirroring the transcriptional signature of endurance training [2][4]. Because ERRs are expressed across multiple tissues including heart, brain, kidney, and liver, pan-ERR agonism also produces effects outside skeletal muscle that are not fully characterised [6].
Risks & side effects
Most important: SLU-PP-332 has no human clinical trial data whatsoever — no safety, pharmacokinetic, or dosing data in humans have been published — and any self-administration constitutes entirely unvalidated experimentation [6][9]. ERR receptors are expressed in the heart, brain, liver, and kidney, meaning systemic ERR agonism may produce serious off-target effects, including cardiovascular, oncological, or immune consequences that remain wholly uncharacterised [6][10].
Common
Serious
- Unknown cardiovascular effects — ERR agonism alters cardiac metabolism; human cardiac safety has not been evaluated [9][10]
- No chronic toxicology data in any species; long-term risks are entirely unknown [6]
- Potential oncological risk — ERRα interactions with cancer signalling pathways raise unresolved concern [10]
- Off-target ERR effects in non-muscle tissues (brain, kidney, liver, immune system) not yet characterised [6]
- Poor or absent oral bioavailability means doses from oral tablet formats may produce unpredictable systemic exposure [13]
- Gray-market supply carries no verified identity, purity, or dose — contamination and mislabelling risks are real [9]
Safety & harm reduction
- Any person outside an IRB-approved research study — no evidence base for human use exists [9]
- Pregnancy or breastfeeding — no reproductive or developmental toxicology data [9]
- Individuals with existing cardiovascular disease — cardiac safety entirely uncharacterised in humans [9][10]
- Athletes subject to anti-doping regulations — detection methods are in development as of 2026 [9]
- Individuals with or at elevated risk of ERRα-linked cancers — unresolved oncological risk signal [10]
- Baseline and periodic ECG / cardiac function if any self-experimentation occurs (cardiovascular effects are uncharacterised) [9]
- Fasting glucose, insulin, HbA1c — compound affects insulin sensitivity pathways [7]
- Lipid panel (cholesterol, triglycerides, HDL) — metabolic shifts observed in mouse models [7]
- Liver enzymes (ALT/AST) — hepatic metabolism via CYP450 is the primary clearance route [14]
- Body composition (lean mass / fat mass) — to detect unexpected wasting or metabolic dysregulation [7]
- CYP450 substrates — SLU-PP-332 is metabolised by hepatic CYP450 enzymes; interactions with co-administered CYP substrates or inhibitors are unstudied [14]
- Insulin sensitisers / antidiabetics (metformin, GLP-1 agonists, SGLT-2 inhibitors) — additive or unpredictable glucose-lowering effects possible given insulin-sensitising activity [7]
- Cardiac medications — given uncharacterised cardiac ERR agonism, interactions with antiarrhythmics or heart failure drugs are unknown [10]
- Other exercise mimetics (GW501516/Cardarine, SR-9009/SR-9011) — mechanistically distinct but combined ERR + PPAR/REV-ERB agonism has not been studied in humans [2]
- No validated human protocol exists; any use is off-label self-experimentation with unknown risk [6][9]
- Animal efficacy studies used intraperitoneal injection twice daily; this route is not applicable to human self-administration [4]
- Oral tablet formats carry significant uncertainty: a 2025 paper developing the orally active analogue SLU-PP-915 explicitly noted SLU-PP-332 'lacks oral bioavailability' [13]
- Verify compound identity and purity via third-party Certificate of Analysis (CoA) before any research use; community-sourced material is uncontrolled [11]
Dosage context
No human dosage has been established. Animal studies used intraperitoneal doses of 10–50 mg/kg/day in rodents [15]; these CANNOT be translated to human equivalents. A 2025 publication explicitly noted SLU-PP-332 "lacks oral bioavailability," making oral tablet dosing formats unvalidated [13]. Community self-experimenters describe subcutaneous use at microgram-range doses, but no pharmacokinetic or safety data support any human dosing regimen [9]. Any dosing context circulating online is speculative and unvalidated.
Sources
- 1.Loti Labs – SLU-PP-332 Research Guide (link unavailable)
- 2.Peptides Institute – SLU-PP-332 Research Profile
- 3.MedChemExpress – SLU-PP-332 Product Page (ERR agonist EC50 data)
- 4.BioRxiv – Billon et al. 2022: Synthetic ERRα Agonist Induces Aerobic Exercise Response
- 5.Wikipedia – SLU-PP-332
- 6.Peptides Institute – SLU-PP-332 Safety & Risks Section
- 7.PMC / J Pharmacol Exp Ther – A Synthetic ERR Agonist Alleviates Metabolic Syndrome
- 8.ResearchGate – SLU-PP-332 and ERRα Agonists Minireview (cardiac/HF)
- 9.Superpower.com – SLU-PP-332 Pan-ERR Agonist Research Tool Guide
- 10.Redfox Peptides – SLU-PP-332 Side Effects: What Researchers Report
- 11.Redfox Peptides – SLU-PP-332 Side Effects (community reports)
- 12.Loti Labs – SLU-PP-332 Preclinical Safety Observations (link unavailable)
- 13.The Peptide Catalog – SLU-PP-332 Dosing Guide (oral bioavailability / SLU-PP-915 note)
- 14.BenchChem PK Guide – In Vivo Pharmacokinetics of SLU-PP-332
- 15.LifeWellMD – SLU-PP-332 Dosage Guidelines (animal dose ranges)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.